Over the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...

What is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...

Biocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...

The US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for ...

Biocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...

Biocon has a insulins manufacturing facility is Malaysia at Johor which has been approved by the National Pharmaceutical Regulatory Authori...

“This is to inform you that Biocon Sdn Bhd, a subsidiary of Biocon, has received the EIR from the USFDA for the pre-approval inspection of ...

USFDA had conducted a pre-approval inspection of Biocon's subsidiary Biocon Sdn BHd's manufacturing facility in Malaysia for Insulin Glargi...

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.

The integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...

US health regulator issued six observations in Form 483 after pre-approval inspection of its insulin drug substance manufacturing facility ...

Torrent Pharmaceuticals and Novo Nordisk began their partnership 25 years ago in 1992 with the manufacture and launch of insulin in 40 IU v...

The facility, set up with an investment of $275 million, is designed to manufacture recombinant human insulin and insulin analogs for the g...

The drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...

Initially, the products from the facility will cater to local markets but they would be taken gradually to global markets, Kiran Mazumdar-S...

Spread over 10,000 square feet, the facility will manufacture pen like delivery devices for people with diabetes in India and other parts o...

Sanofi, though its Indian entity Shantha Biotechnics, will set up an insulin production facility in Telangana, involving an investment of R...